Tang Hua-Yu, Zhao Yu, Li Yu-Zhi, Wang Tian-Shu
Second Ward of Orthopedis Department, First Affiliated Hospital of Jiamusi University, Jiamusi, China.
Department of Orthopedis, Huludao Central Hospital, Huludao, China.
Medicine (Baltimore). 2019 Apr;98(15):e15155. doi: 10.1097/MD.0000000000015155.
Previous clinical trials have reported that etoricoxib has been utilized to treat ankylosing spondylitis (AS) effectively. However, no study systematically investigated the efficacy and safety of etoricoxib for patients with AS. In this systematic review, we will assess the efficacy and safety of etoricoxib for AS.
The following electronic databases will be searched from inception to the February 1, 2019: Cochrane Library, Embase, PubMed, Cumulative Index to Nursing and Allied Health Literature, China National Knowledge Infrastructure, Chinese Biomedical Literature Database, and Chinese Scientific Journal Database. This study will include randomized controlled trials that explore the efficacy and safety of etoricoxib for AS. The primary outcome is pain intensity, as measured by any pain scales, such as Numerical Rating Scale. The secondary outcomes consist of AS function, as measured by Bath Ankylosing Spondylitis Functional Index, or other tools; quality of life, as assessed by Ankylosing Spondylitis Quality of Life questionnaire or any other relevant instruments; as well as adverse events. Two authors will independently carry out the study selection, data extraction, and risk of bias assessment. Statistical analysis will be performed by using RevMan 5.3 software.
This systematic review will provide a detailed summary of present evidence related to the efficacy and safety of etoricoxib for patients with AS.
The results of this study may provide management guidance for AS treated by etoricoxib.
This systematic review dose not needs ethical approval, because it will not analyze individual patient data. The findings of this study are expected to publish through a peer-reviewed journal.
CRD42019124768.
既往临床试验报道称,依托考昔已被用于有效治疗强直性脊柱炎(AS)。然而,尚无研究系统调查依托考昔对AS患者的疗效和安全性。在本系统评价中,我们将评估依托考昔治疗AS的疗效和安全性。
将检索以下电子数据库,检索时间从建库至2019年2月1日:Cochrane图书馆、Embase、PubMed、护理学与健康照护领域累积索引、中国知网、中国生物医学文献数据库和中国科学期刊数据库。本研究将纳入探讨依托考昔治疗AS疗效和安全性的随机对照试验。主要结局为疼痛强度,采用任何疼痛量表进行测量,如数字评定量表。次要结局包括采用巴斯强直性脊柱炎功能指数或其他工具测量的AS功能;采用强直性脊柱炎生活质量问卷或任何其他相关工具评估的生活质量;以及不良事件。两名作者将独立进行研究筛选、数据提取和偏倚风险评估。将使用RevMan 5.3软件进行统计分析。
本系统评价将详细总结目前有关依托考昔治疗AS患者疗效和安全性的证据。
本研究结果可为依托考昔治疗AS提供管理指导。
本系统评价无需伦理批准,因为它不会分析个体患者数据。本研究结果预计将通过同行评审期刊发表。
CRD42019124768。